JP2017535546A - 新規な方法 - Google Patents

新規な方法 Download PDF

Info

Publication number
JP2017535546A
JP2017535546A JP2017525839A JP2017525839A JP2017535546A JP 2017535546 A JP2017535546 A JP 2017535546A JP 2017525839 A JP2017525839 A JP 2017525839A JP 2017525839 A JP2017525839 A JP 2017525839A JP 2017535546 A JP2017535546 A JP 2017535546A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
acceptable salt
prodrug
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017525839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535546A5 (enExample
Inventor
マーク・エフ・ペレティエ
ジョージ・ウィリアム・ファー
ポール・ロバート・マクガーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeromics Inc
Original Assignee
Aeromics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeromics Inc filed Critical Aeromics Inc
Publication of JP2017535546A publication Critical patent/JP2017535546A/ja
Publication of JP2017535546A5 publication Critical patent/JP2017535546A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C07F9/145—Esters of phosphorous acids with hydroxyaryl compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017525839A 2014-11-13 2015-11-13 新規な方法 Withdrawn JP2017535546A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462079541P 2014-11-13 2014-11-13
US62/079,541 2014-11-13
US201462080241P 2014-11-14 2014-11-14
US62/080,241 2014-11-14
PCT/US2015/060731 WO2016077787A1 (en) 2014-11-13 2015-11-13 Novel methods

Publications (2)

Publication Number Publication Date
JP2017535546A true JP2017535546A (ja) 2017-11-30
JP2017535546A5 JP2017535546A5 (enExample) 2018-12-20

Family

ID=55955168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525839A Withdrawn JP2017535546A (ja) 2014-11-13 2015-11-13 新規な方法

Country Status (10)

Country Link
US (1) US20180042873A1 (enExample)
EP (1) EP3218354A4 (enExample)
JP (1) JP2017535546A (enExample)
CN (1) CN107207417A (enExample)
AU (1) AU2015346076A1 (enExample)
CA (1) CA2966950A1 (enExample)
IL (1) IL252086A0 (enExample)
SG (1) SG11201703801SA (enExample)
TW (1) TW201716059A (enExample)
WO (1) WO2016077787A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
CN105899223A (zh) 2013-10-28 2016-08-24 加利福尼亚大学董事会 转移性前列腺癌的治疗
CN106163506A (zh) 2013-11-06 2016-11-23 埃罗米克斯公司 新配方
US11117909B2 (en) 2016-05-13 2021-09-14 Aeromics, Inc. Crystals
CN110790787B (zh) * 2019-11-12 2022-06-14 广东药科大学 一类水溶性前药、其制备方法及其作为药物的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263657B2 (en) * 2000-12-18 2012-09-11 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the production and release of inflammatory cytokines
CA2487900A1 (en) * 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Immunity-related protein kinase inhibitors
WO2003103656A1 (ja) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Ｏ−置換ヒドロキシアリール誘導体
BRPI0807918A2 (pt) * 2007-02-17 2017-05-16 Harvard College composições e método para preservação de tecido
EP2201946A4 (en) * 2007-10-23 2012-01-25 Inst Med Molecular Design Inc HAMMER OF PAI-1 PRODUCTION
WO2012125749A2 (en) * 2011-03-14 2012-09-20 Io Therapeutics, Inc. INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS
KR102200176B1 (ko) * 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법

Also Published As

Publication number Publication date
AU2015346076A1 (en) 2017-06-15
IL252086A0 (en) 2017-07-31
EP3218354A1 (en) 2017-09-20
CA2966950A1 (en) 2016-05-19
SG11201703801SA (en) 2017-06-29
EP3218354A4 (en) 2018-06-13
US20180042873A1 (en) 2018-02-15
TW201716059A (zh) 2017-05-16
WO2016077787A1 (en) 2016-05-19
CN107207417A (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
US20020132220A1 (en) Use of selectin antagonists in organ preservation solutions
JP2017535546A (ja) 新規な方法
JP2017535546A5 (enExample)
JP5907357B2 (ja) 移植臓器生着促進剤
ES2363914T3 (es) Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
PENNock et al. Survival of primates following orthotopic cardiac transplantation treated with total lymphoid irradiation and chemical immune suppression
CA2896073C (en) Stimulation and enhancement of regeneration of tissues
US8809303B2 (en) Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
CA3092596C (en) Novel aminothiol reduction of ischemia-reperfusion-induced cell death
Finger Organ preservation
JP6878418B2 (ja) 移植片拒絶反応の処置方法
WO2002017959A2 (en) Immunosuppression using piceatannol and a calcineurin inhibitor
Monache et al. Effect of pharmacological modulation of liver P-glycoproteins on cyclosporin A biliary excretion and cholestasis a study in isolated perfused rat liver
WO2017019214A1 (en) Donor organ pre-treatment formulation
HK40031657A (en) Novel aminothiol reduction of ischemia-reperfusion-induced cell death
KR20250120401A (ko) 이식물 및 수혜자의 생존을 연장하기 위한 조성물 및 방법
JP2017057184A (ja) 虚血再灌流障害軽減用組成物
WO2017021914A1 (en) Abscisic acid for reducing damage to transplanted tissue
JP2019522052A (ja) 抗細菌組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181107

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190802